Dear Colleagues,

As you are aware, there is a lack of safe and potent adjuvants to aid in developing new and improved vaccines. Due to the uniqueness of each disease and the specific types of immune responses to be modulated, various kinds of adjuvants are needed to induce optimal immune responses against a particular disease. Vaccine adjuvants may also need to be tailored for use in different age groups due to the age-related differential immune responses to vaccines. In the past, adjuvant development has mainly relied on empirical experience, and only a few adjuvants have been approved for human use since the first(Alum) was discovered over 90 years ago. Significant advances have been made in the last three decades in understanding how adjuvants work. Modern techniques, such as high-throughput screening and in-silico screening, have also been used to discover novel adjuvants for human use. The last two decades have also seen increased investment in novel adjuvant development. These efforts are expected to accelerate novel adjuvant discovery and development. This Special Issue welcomes submissions of adjuvant discovery and development in diverse types of vaccines (e.g., subunit, mRNA-based) against infectious diseases, cancer, or immune-mediated diseases. This issue also welcomes submissions of adjuvant mechanism studies and explorations of combinatorial adjuvants in vaccine development.

Dr. Xinyuan Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• vaccine adjuvant
• mechanism
• combinatorial adjuvant
• subunit
• mRNA
• vaccine discovery
• vaccine development